Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
January 02, 2024 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
December 26, 2023 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
November 09, 2023 16:01 ET
|
Oncternal Therapeutics
The first patient was dosed in our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved...
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results
November 02, 2023 16:05 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
October 26, 2023 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
October 25, 2023 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
October 05, 2023 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
September 07, 2023 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
August 10, 2023 16:01 ET
|
Oncternal Therapeutics
Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor...
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
August 03, 2023 16:30 ET
|
Oncternal Therapeutics
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...